More on AUPH

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+75.0% Growth)
- Ratings (6.7 Score)
- Holders

Upcoming Events

- Earnings (Posted Today)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Aurinia Pharmaceuticals (NQ:AUPH)
Delayed: 16.13 +0.94 (6.19%)
Prev. Close $15.19  
Open$15.93 
52 Wk High$5.69 
52 Wk Low$1.42 
Day High$16.35 
Day Low$15.70 
P/E N/A  
EPS$0.00 
Volume2,235,458 


Aug 6, 2026 08:22 AM Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 5c
Aug 6, 2026 08:17 AM Form 10-Q Aurinia Pharmaceuticals For: Jun 30
Aug 6, 2026 08:03 AM Form 8-K Aurinia Pharmaceuticals For: Aug 06
Aug 6, 2026 08:00 AM Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Jul 6, 2026 08:03 AM Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs
Jul 6, 2026 08:00 AM Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Jun 8, 2026 04:14 PM Form 4 Aurinia Pharmaceuticals For: Jun 04 Filed by: Johnson Craig A
Jun 8, 2026 04:12 PM Form 4 Aurinia Pharmaceuticals For: Jun 04 Filed by: Goetz Kathleen
Jun 8, 2026 04:11 PM Form 4 Aurinia Pharmaceuticals For: Jun 04 Filed by: Nova Tina Susan
Jun 8, 2026 04:09 PM Form 4 Aurinia Pharmaceuticals For: Jun 04 Filed by: Bailey Jeffrey Allen
View All Articles

Entities mentioned with AUPH

View All Entities